Faron Pharmaceuticals Oy

FARON · Nasdaq Helsinki · Healthcare

0.41EUR +0.2%last day

Price as of 2 October 2026

The price over the past year, with dividends: −80.0%

Performance

1 month

0.0%

1 year

−80.0%

3 years, per year

−51.9%

5 years, per year

−37.5%

Largest fall, 3 years

−90.3%

Below the peak now

−93.3%

Volatility, 1 year

84.3%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

7.2

Dividend yield

0.0%

Return on equity

–

Net margin

–

Market value

95 m USD

Quality, value and trend

Where Faron Pharmaceuticals stands against every Nordic stock today. 100 is best.

Value1

The price measured against earnings, assets and cash flow. Better than 1% of Nordic stocks.

Trend7

The price development over the past year. Better than 7% of Nordic stocks.

About Faron Pharmaceuticals

Faron Pharmaceuticals Oy is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 36 employees.

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis